A future without surgery for stomach and colon cancers?

NCT ID NCT07775859

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study tests whether people with certain gastrointestinal cancers—like stomach, esophageal, or colorectal—can safely skip radical surgery after responding well to precision therapies such as immunotherapy or targeted drugs. Participants with specific molecular markers will be evaluated by a team of experts and may receive non-operative management, local treatment, or surgery. The goal is to see if organ preservation can offer similar cancer control while improving function and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Molecular biomarker-guided non-operative management and organ preservation strategy after precision therapy (immune checkpoint inhibitors or targeted therapy)
What this could lead to
If successful, this could establish a new paradigm where some gastrointestinal cancers are managed without radical surgery, preserving organs and improving quality of life while maintaining cancer control.
What could go wrong
This is an early-stage, single-center study, and organ preservation may not provide the same long-term cancer control as surgery. There is also a risk of disease recurrence without radical resection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.